ClinicalTrials.gg
CompletedNCT04760769TEMPO-4Updated Dec 23, 2025

Open-label Trial in Parkinson's Disease (PD)

A Phase 3 interventional study of Tavapadon in Parkinson Disease, sponsored by AbbVie. Completed at 140 sites in 14 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
992
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
Largest of 11
992 · median 57
Started
2021
the only one that year
Phase 3
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
4 of 11
AbbVie

Among the 11 studies testing tavapadon in Parkinson Disease, this one has the largest enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 9th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinsonian Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Movement Disorders
  • Neurodegenerative Diseases
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Rollover participants are eligible for the study if they met the following inclusion criteria:

  • Participants who complete the 27-week double-blind Treatment Period of Trial CVL-751-PD-001 (NCT04201093) or Trial CVL-751 PD-003 (NCT04542499) or the 27-week double-blind Treatment Period and 10-day Safety/Withdrawal Assessment Period of Trial CVL-751-PD-002 (NCT04223193) and enter this trial within 72 hours after completing the last trial visit in the double-blind trial. Rollover participants from Trial CVL-751-PD-003 must continue to use levodopa/carbidopa (or levodopa/benserazide) for the duration of the trial.
  • Sexually active men or women of must agree to use acceptable (at minimum) or highly effective , or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
  • Participants who are capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Participants who are willing and able to refrain from any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.
  • Participant who, in the judgement of the investigator, demonstrated adequate compliance with the IMP and protocol requirements in the double-blind trial.

Key Exclusion criteria:

Rollover participants are excluded from the trial if any of the following met:

  • Participants who do not enroll in this open-label trial within 72 hours after completing the last trial visit in the double-blind trial
  • Participants who answer "yes" on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer "yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
  • Participants who had previously been enrolled in this open-label trial and had subsequently withdrawn.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
992 participants (actual)

Study arms

  • Experimental
    Tavapadon

    Participants will receive a Tavapadon tablet at a dose of 5 milligrams (mg) to 15 mg once daily (QD) orally during 58-week treatment period.

    Drug: Tavapadon

Interventions

  • Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.

    Also known as: PF-06649751, CVL-751

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. Any AE occurring following the start of treatment or occurring before treatment but increasing in severity afterward were counted as treatment-emergent AE (TEAE). Clinically significant abnormalities in Clinical Laboratory Evaluations, Vital Signs, Physical and Neurological evaluations and ECGs will be reported as TEAEs.

    Time frame: 62 Weeks

  2. Number of Participants Who Discontinued Study Treatment

    A participant may discontinue the study treatment due to any of the following reasons: adverse event, death, worsening of PD symptoms to such an extent that, in the judgement of the investigator, the participant requires additional anti-PD medications, treatment with a prohibited concomitant medication, noncompliance with the trial schedule or procedures, withdrawal of consent, pregnancy, investigator discretion.

    Time frame: 62 Weeks

  3. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS)

    QUIP-RS is a global screening instrument that assesses impulse control disorders (ICDs) and related disorders (punding, hobbyism, and dopamine dysregulation syndrome) in participants with PD. The QUIP-RS has 4 primary questions that pertain to commonly reported thoughts, urges/desires, and behaviors associated with ICDs, each of which is applied to 4 ICDs (compulsive gambling, buying, eating, sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). The QUIP-RS uses a 5-point Likert scale (score 0-4 \[0 means "never" and 4 means "very often"\] for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating greater severity (frequency) of symptoms. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.

    Time frame: 58 Weeks

  4. Epworth Sleepiness Scale (ESS)

    ESS is a scale that is intended to measure daytime sleepiness. It assesses the likelihood of dozing off or falling asleep in the following common situations: sitting and reading, sitting inactive in a public place as a passenger in a car for an hour or more without stopping for a break, lying down to rest when circumstances permit, sitting and talking to someone, sitting quietly after a meal without alcohol, and in a car while stopped for a few minutes in traffic or at a light. Each situation is rated as 0 = would never nod off, 1 = slight chance of nodding off, 2 = moderate chance of nodding off, or 3 = high chance of nodding off. A score greater than or equal to (\> =) 10 indicates that the participant may need to get more sleep, improve sleep practices, or seek medical attention to determine why he or she is sleepy.

    Time frame: 58 Weeks

  5. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

    Time frame: 60 Weeks

  6. Study Medication Withdrawal Questionnaire (SMWQ)

    SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with Investigational medicinal product (IMP). The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which the first question "Have you been craving amphetamine or methamphetamine?" is replaced with "Have you been craving the trial medication?" This change is intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. Participants will complete the SMWQ onsite when they are at a designated trial visit; on days when the participant is not onsite, they will complete the SMWQ remotely.

    Time frame: 60 Weeks

  7. Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and III

    The MDS-UPDRS is a multidimensional scale that assesses the motor and non-motor impacts of PD across 4 parts. Part I, non-motor aspects of experiences of daily living, comprises 13 items, 6 of which are rated by the physician (Part IA) and 7 of which are rated by the participant (Part IB). Part II, motor aspects of experiences of daily living, comprises 13 items that are rated by the participant. Part III, motor examination, comprises 18 items that are assessed by the investigator (resulting in 33 scores by location and lateralization). Part IV, motor complications, comprises 6 item (3 items for dyskinesia and 3 items for fluctuation) and requires the physician to use historical and objective information to assess dyskinesia and motor fluctuations. Each item of all the parts will be rated on a scale from 0 to 4 on which 0 = normal, 1=slight, 2=mild, 3=moderate, and 4=severe. Change from baseline in MDS-UPDRS parts I, II and III combined score will be assessed.

    Time frame: 60 Weeks

  8. Change From Baseline in the Hauser diary

    The Hauser diary (Hauser et al, 2000) assesses participant-defined clinical status over a period of time and provides a tool for assessment of the change in "off" time and "on" time with troublesome dyskinesia (which is a more accurate reflection of clinical response than "off" time alone). The Hauser diary asks participants to rate their mobility for each 30-minute period and to record their status for the majority of the period in 1 of 5 categories as: "on" time without dyskinesia, "on" time with nontroublesome dyskinesia, "on" time with troublesome dyskinesia, "off" time, or asleep.

    Time frame: 58 Weeks

  9. Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index

    EQ-5D-5L is a survey instrument used for participant-reported outcome that measures health in 5 dimensions. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels of perceived problems (1 = no problem, 2 = slight problems, 3 = moderate problems, 4 = severe problems, 5 = extreme problems). Participant selects an answer for each of 5 dimensions considering the response that best matches his/her health "today". The digits for the 5 dimensions are combined into a 5-digit number that describes the participant's health state.

    Time frame: Baseline (Day 1), Weeks 32 and 58

  10. Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scores (VAS)

    EQ-5D-5L VAS is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. The EQ-5D-5L VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

    Time frame: Baseline (Day 1), Weeks 32 and 58

07

Study locations

140 sites
  • Birmingham, Alabama
    Birmingham, Alabama 35233, United States
  • Pheonix, Arizona
    Phoenix, Arizona 85004, United States
  • Little Rock, Arkansas
    Little Rock, Arkansas 72205, United States
  • Fountain Valley, California
    Fountain Valley, California 92708, United States
  • Fresno, California
    Fresno, California 93710, United States
  • Los Angeles, California
    Los Angeles, California 90048, United States
  • Pasadena, California
    Pasadena, California 91105, United States
  • Reseda, California
    Reseda, California 91335, United States
  • Englewood, Colorado
    Englewood, Colorado 80113, United States
  • Florida, United States
    Adventura, Florida 33180, United States
  • Boca Raton, Florida
    Boca Raton, Florida 33486, United States
  • Coral Springs, Florida
    Coral Springs, Florida 33067, United States
  • Maitland, Florida
    Maitland, Florida 32751, United States
  • Naples, Florida
    Naples, Florida 34102, United States
  • Ocala, Florida
    Ocala, Florida 34470, United States
  • Port Charlotte, Florida
    Port Charlotte, Florida 33980, United States
  • Port Orange, Florida
    Port Orange, Florida 32127, United States
  • Tampa, Florida
    Tampa, Florida 33615, United States
  • Winter Park, Florida
    Winter Park, Florida 32792, United States
  • Augusta, Georgia
    Augusta, Georgia 30912, United States
  • Chicago, Illinois
    Chicago, Illinois 60612, United States
  • Winfield, Illinois
    Winfield, Illinois 60190, United States
  • Kansas City
    Kansas City, Kansas 66160, United States
  • Lexington, Kentucky
    Lexington, Kentucky 40536, United States
  • Scarborough, Maine
    Scarborough, Maine 04074, United States
  • Boston, Massachusettes
    Boston, Massachusetts 02215, United States
  • Lawrence, Massachusetts
    Lawrence, Massachusetts 01843, United States
  • East Lansing, Michigan
    East Lansing, Michigan 48824, United States
  • West Bloomfield
    West Bloomfield, Michigan 48322, United States
  • Las Vegas, Nevada
    Las Vegas, Nevada 89106, United States
  • Camden, New Jersey
    Camden, New Jersey 08103, United States
  • Albany, New York
    Albany, New York 12208, United States
  • Syracuse, New York
    Syracuse, New York 13210, United States
  • Asheville, North Carolina
    Asheville, North Carolina 28806, United States
  • Durham, North Carolina
    Durham, North Carolina 27705, United States
  • Cincinnati, Ohio
    Cincinnati, Ohio 45212, United States
  • Cleveland, Ohio
    Cleveland, Ohio 44195, United States
  • Columbus, Ohio
    Columbus, Ohio 43221, United States
  • Dayton, Ohio
    Dayton, Ohio 45459, United States
  • Toledo, Ohio
    Toledo, Ohio 43614, United States
  • Philadelphia, Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
  • Memphis, Tennessee
    Memphis, Tennessee 38157, United States
  • Georgetown, Texas
    Georgetown, Texas 78628, United States
  • Houston, Texas
    Houston, Texas 77030, United States
  • Lubbock, Texas
    Lubbock, Texas 79410, United States
  • Round Rock, Texas
    Round Rock, Texas 78681, United States
  • Burlington, Vermont
    Burlington, Vermont 05401, United States
  • Richmond, Virginia
    Richmond, Virginia 23229, United States
  • Richmond, Virginia
    Richmond, Virginia 23233, United States
  • Virginia Beach, Virginia
    Virginia Beach, Virginia 23456, United States
  • Kirkland, Washington
    Kirkland, Washington 98034, United States
  • Spokane, Washington
    Spokane, Washington 99202, United States
  • Erina, New South Wales
    Erina, New South Wales 2250, Australia
  • Kogarah
    Kogarah, New South Wales 2217, Australia
  • Macquarie Park, New South Wales
    Sydney, New South Wales 2109, Australia
  • Woolloongabba, Queensland
    Woolloongabba, Queensland 4102, Australia
  • Clayton, Victoria
    Clayton, Victoria 3168, Australia
  • Parkville, Victoria
    Parkville, Victoria 3050, Australia
  • Medical center VITA1, Pleven
    Pleven, 5800, Bulgaria
  • Pleven, Bulgaria
    Pleven, 5800, Bulgaria
  • Pleven
    Pleven, 5800, Bulgaria
  • Multiprofile Hospital, Sofia
    Sofia, 1113, Bulgaria
  • Sofia
    Sofia, 1142, Bulgaria
  • Sofia
    Sofia, 1407, Bulgaria
  • Sofia
    Sofia, 1431, Bulgaria
  • Ottawa, Ontario
    Ottawa, Ontario K1Y4E9, Canada
  • Toronto, Ontario
    Toronto, Ontario M5T 2S8, Canada
  • Chocen
    Choceň, Chocen 56501, Czechia
  • Prague, Czech Republic
    Prague, Czech Republic 150 00, Czechia
  • Prague,
    Prague, 100 00, Czechia
  • Prague,
    Prague, 160 00, Czechia
  • Rychnov nad Kněžnou
    Rychnov nad Kněžnou, 516 01, Czechia
  • Creteil,
    Créteil, Creteil 94010, France
  • Boulevard Pinel, Bron
    Bron, 69500, France
  • Grenoble cedex
    Grenoble, 38043, France
  • Nancy
    Nancy, 54035, France
  • Nîmes cedex 09
    Nîmes, 30029, France
  • Strasbourg
    Strasbourg, 67098, France
  • Toulouse Cedex 9
    Toulouse, 31059, France
  • Muenster
    Münster, Muenster 48149, Germany
  • Bad Homburg
    Bad Homburg, 61348, Germany
  • Berlin
    Berlin, 12163, Germany
  • Bochum
    Bochum, 44791, Germany
  • Gera
    Gera, D-07551, Germany
  • Haag in Oberbayern
    Haag in Oberbayern, 83527, Germany
  • Klinikum rechts der Isar der TU München
    Munich, 81675, Germany
  • Muenchen
    München, 81377, Germany
  • Stadtroda
    Stadtroda, 07646, Germany
  • Budapest
    Budapest, 1135, Hungary
  • Pecs
    Pécs, 7623, Hungary
  • Tatabanya
    Tatabánya, 2800, Hungary
  • Haifa
    Haifa, 3109601, Israel
  • Petah Tiqva
    Petah Tikva, 49100, Israel
  • Ramat Gan
    Ramat Gan, 5265601, Israel
  • Shoham
    Shoham, 6083531, Israel
  • Tel Aviv
    Tel Aviv, 6100000, Israel
  • Ancona
    Ancona, 60126, Italy
  • Cassino
    Cassino, 03043, Italy
  • Milano, Italy
    Milan, 20126, Italy
  • Milano
    Milan, 20132, Italy

Showing the first 100 of 140 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2025, 57 months.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 57 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2021
First posted
Feb 18, 2021
StartActual
Feb 24, 2021
Primary completionActual
Dec 1, 2025
CompletionActual
Dec 1, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04760769
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Feb 24, 2021
Primary completion
Dec 1, 2025
Completion
Dec 1, 2025
Last update
Dec 23, 2025

Study contacts

ABBVIE Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion